scholarly journals Nestin Protein Is Phosphorylated in Adult Neural Stem/Progenitor Cells and Not Endothelial Progenitor Cells

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Jun Namiki ◽  
Sayuri Suzuki ◽  
Takeshi Masuda ◽  
Yasushi Ishihama ◽  
Hideyuki Okano

An intermediate filament protein, Nestin, is known as a neural stem/progenitor cell marker. It was shown to be required for the survival and self-renewal of neural stem cells according to the phenotypes of Nestin knockout mice. Nestin expression has also been reported in vascular endothelial cells, and we recently reported Nestin expression in proliferating endothelial progenitor cells, but not in mature endothelial cells. Using quantitative phosphoproteome analysis, we studied differences in phosphorylation levels between CNS Nestin in adult neural stem cells and vascular Nestin in adult bone-marrow-derived endothelial progenitor cells. We detected 495 phosphopeptides in the cell lysates of adult CNS stem/progenitor cells and identified 11 significant phosphorylated amino acid residues in the Nestin protein. In contrast, endothelial progenitor cells showed no significant phosphorylation of Nestin. We also measured neoplastic endothelial cells of the mouse brain and identified 13 phosphorylated amino acid residues in the Nestin protein. Among the 11 phosphorylated amino acids of adult CNS Nestin, five (S565, S570, S819, S883, and S886) were CNS Nestin-specific phosphorylation sites. Detection of the CNS-specific phosphorylation sites in Nestin, for example, by a phospho-specific Nestin antibody, may allow the expression of CNS Nestin to be distinguished from vascular Nestin.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1821-1821
Author(s):  
Morayma Reyes ◽  
Jeffrey S. Chamberlain ◽  
Akshay Krishnamurty

Abstract We report here the characterization of endothelial cells from skeletal muscles by fluorescence-activated cell sorting on the basis of cell surface antigen expression for Sca-1, CD34 and CD31. Sca-1 is a marker of hematopoietic stem cells, although it can be expressed by other cells including endothelial cells. CD34 is also a marker of hematopoeitic stem cells and endothelial cells. Satellite cells of the skeletal muscles express CD34 but are negative for Sca-1 and CD31. CD31 or PECAM is a well recognized endothelial marker expressed by endothelium of multiple organs, however, its expression by microvascular endothelial cells of the skeletal muscle has not been previously characterized. Reports by others have described myo-endothelial progenitor cells in the interstitial spaces of the skeletal muscles based on the expression of CD34. These cells are Sca-1+ but negative for CD31 and other endothelial markers but are capable of myogenic and endothelial differentiation. Because hematopoietic cells express some of these markers, we used CD45 to exclude all hematopoietic cells in the muscles. We used a cocktail of antibodies to identify and characterize endothelial cells derived from skeletal muscles. For this whole body mouse muscles (n=20 C57BL6 mice, age 2-18 months) were harvested, digested and analyzed by flow cytometry. We found a very distinct and homogenous population identified as Sca-1+/CD34+/CD31+/CD45−. This population represents 5–10% of all mononuclear cells derived from the muscles. Triple staining of skeletal muscle using these markers highlights muscular vessels. In order to further characterize these cells, we FACS-sorted this population as well as Sca-1+/CD34+/CD31− and Sca-1−/CD34+/CD31− cells and analyzed then on cytospin by staining for endothelial as well as non-endothelial markers. While the majority of the cells within the Sca-1+/CD34+/CD31+ are positive for vWF (a marker of mature endothelial cells), the other two populations (Sca-1+/CD34+/CD31-and Sca-1−/CD34+/CD31−) were negative for vWF. Sca-1+/CD34+/CD31+ cells are also dim for Flk-1 and Tie-2. Interestingly, a minor population within this phenotype (Sca-1+/CD34+/CD31+) express syndecan-4 and CXCR4, markers important for migration and mobilization of stem cells. Studies to determine if this minor population contains more primitive endothelial progenitor cells are ongoing. In addition, Sca-1+/CD34+/CD31+ are negative for all the myogenic markers (Pax3, Pax7, MyoD, Myf5, Myf6 and Myogenin). In order to determine if muscle ECs can be expanded, Sca-1+/CD34+/CD31+ were sorted and cultured on different extracellular matrices: collagen, matrigel and fibronectin using DMEM and 10% FCS supplemented with 10ng/mL of VEGF. ECs from muscle grow better on fibronectin and can be passaged for more than 10 cell doublings. When seeded on matrigel, muscle ECs can make vascular tubes. Finally, when sorted Sca-1+/CD34+/CD31+ derived from ROSA26 mice are transplanted intramuscularly in the tibialis anterior muscle, 2 weeks after transplant bgal (lacZ)-positive cells can be detected in multiple vessels, demonstrating the angiogenic potential of these cells. Therefore, Sca-1+/CD34+/CD31+ are “bona fide” endothelial cells of the skeletal muscles. Understanding the biology of these cells is crucial to develop treatment for peripheral vascular disease and other ischemic diseases of the muscles.


2011 ◽  
Vol 26 (S2) ◽  
pp. 1187-1187
Author(s):  
R. Kollmar ◽  
M. Herrmann ◽  
T. Stöckl ◽  
U. Weinzierl ◽  
S. Schwab ◽  
...  

ObjectiveWe examined leukocyte numbers, circulating endothelial progenitor cells (CD34+, CD133+), circulating mesenychmal stem cells (CD105+) and circulating endothelial cells (CD146+) at the beginning, after 4 weeks and at the end of an inpatient antidepressant treatment.Methods24 insufficiently pretreated inpatients with major depression were included. At admission, after four weeks and at demission blood samples were obtained, and cell numbers were counted by flow cytometric analysis (FACS). At each examination the severity of the depression was evaluated with the Beck Depression Inventory (BDI). We were especially interested in the changes of cell numbers during the antidepressant treatment. The data were statistically analyzed using SPSS 14.0.ResultsThe mean BDI score fell from 34 ± 7 at the beginning to 26.5 ± 6.6 after four weeks and 13.5 ± 5.7 at demission. The longer the overall duration of the depressive illness, the higher the number of leukocytes at admission (P < 0.0001). The lower the depression score at demission, the lower the final number of leukocytes (P < 0.001). During the antidepressant treatment the BDI depression score improved significantly (P < 0.0001). The number of CD146+ cells showed a significant decrease (P < 0.006). We did not find any significant changes of circulating CD34+, CD105+, or CD133+ cells during the antidepressant treatment.ConclusionsThe leukocyte results suggest an activation of the immune system in major depression and a deactivation due to antidepressant treatment.


Blood ◽  
2007 ◽  
Vol 110 (3) ◽  
pp. 806-814 ◽  
Author(s):  
Shulamit Levenberg ◽  
Janet Zoldan ◽  
Yaara Basevitch ◽  
Robert Langer

Abstract Growing interest in using endothelial cells for therapeutic purposes has led to exploring human embryonic stem cells as a potential source for endothelial progenitor cells. Embryonic stem cells are advantageous when compared with other endothelial cell origins, due to their high proliferation capability, pluripotency, and low immunogenity. However, there are many challenges and obstacles to overcome before the vision of using embryonic endothelial progenitor cells in the clinic can be realized. Among these obstacles is the development of a productive method of isolating endothelial cells from human embryonic stem cells and elucidating their differentiation pathway. This review will focus on the endothelial potential of human embryonic stem cells that is described in current studies, with respect to the differentiation of human embryonic stem cells to endothelial cells, their isolation, and their characterization.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5449-5449
Author(s):  
Muhamed Baljevic ◽  
Sergey V Shmelkov ◽  
Daniel J Nolan ◽  
Andrea T Hooper ◽  
Adilia Hormigo ◽  
...  

Abstract CD133, a pentaspan surface antigen, is considered a marker of tissue-specific stem cells, including hematopoietic stem cells and endothelial progenitors. We and others have previously shown that CD133 expression is high on endothelial progenitor cells; that it is downregulated during their differentiation and that it is not found on mature endothelium. In addition, CD133+ cells in brain tumors were shown to exhibit features of cancer stem cells. Recent report showed that CD133+ tumor cells are located in perivascular niches in astrocytomas and glioblastomas. It was also demonstrated that in glioblastomas, CD133+ cancer stem cells are tightly associated with tumor vasculature and that signals from endothelial cells are the key factors in self-renewal and proliferation of cancer stem cells. However, the contribution of CD133+ endothelial progenitor cells to tumor angiogenesis remains unknown. We sought to investigate the role of CD133+ cells in human brain tumors and their relation to endothelial progenitor cells and to the mature endothelium. To this end we examined tumor samples resected from patients with glioblastomas. Histological and immunohistochemical analyses revealed that CD133+ cells in these tumors are predominantly endothelial cells as demonstrated by co-staining with CD31 and CD133. We further analyzed a population of endothelial cells using multicolor flow cytometry analysis and we demonstrated that on average 60% of endothelial cells, as defined by the expression of CD31 and VE-cadherin, also express CD133. However, we also found significant heterogeneity between glioblastomas obtained from different patients. Additionally, CD133 was not expressed on CD45−CD31+ subpopulation in meningiomas. Taken together, we demonstrated that high percentage of endothelial cells in glioblastomas expresses CD133, while CD133 could also be found on other cell types within the tumor. Furthermore, our data suggest that tumor vasculature might be enriched with bone marrow derived hemangiogenic progenitors.


Sign in / Sign up

Export Citation Format

Share Document